ClinicalTrials.gg
RecruitingNCT06968871Updated Oct 30, 2026

Ameliorated Pap Tests and Cervical Cancer Screening Participation

An interventional study of Modified Pap test in Cervical Cancer Screening and Cervical Cancer Screening Methods, sponsored by National Taiwan University Hospital. Recruiting at 5 sites in Taiwan. Open to female participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 30, 2026Enrollment updatedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
850
Allocation
Randomized
Ages
25 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital — 2 open to participants now, 2 under way, 1 of them phase 3. Uterine Cervical Neoplasms · National Taiwan University Hospital.

Started
2026
the only one that year
No phase
4 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, this one is the only one that started in 2026, is one of 4 with no phase, and was the 14th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

2 of the 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 25 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Uterine Cervical Neoplasms by National Taiwan University Hospital, or all of them as a file.
02

Study summary

The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.

The present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.

Read the detailed description

Participants: This project expects to include women just before they undergo Pap smear screening at the NTUH Healthcare System. We include eligible women aged 25 or above who have not yet undergone Pap tests from 2026 through 2029. Excluded are those who have ongoing menstruation and those who are pregnant or incapable of understanding the numeric pain scales. Women who have any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer), previous hysterectomy, previous pelvic surgery or radiotherapy, active vaginal or uterus infection, and analgesic use within 24 hours are excluded due to potential interference with pain intensity. The study protocol was approved by the NTUH Research Ethics Committee. During the recruitment process, every eligible participant is fully informed of this trial's aim, design, and content, except for the intervention details. All participants should provide written informed consent. This study is conducted according to the Declaration of Helsinki and is registered at ClinicalTrials.gov.

Sample size estimation: To achieve 90% statistical power at a two-sided α level of 0.05 for detecting an increase in 3-year cervical cancer screening participation from 30% to 50%, the Year 1 target sample size was estimated at a minimum of 248 participants (180 at NTUH Main Hospital and 68 across branch hospitals) in a 1:1 allocation ratio. We will continue recruiting at least 200 new participants annually from Year 2 (2027) through Year 4 (2029)-setting a cumulative enrollment target of 850 in 2029, planned to run through 2032.

Randomization and blinding: Eligible participants are randomly assigned to either the group receiving the traditional Pap test or the modified Pap test. Computer-generated random numbers are employed for simple randomization with a 1:1 allocation ratio. All participants are kept unaware of any information about group allocation throughout the study period. The operators performing the procedure are not informed by the assistants whether to intervene until a specimen is prepared for cervical cytology. The delayed disclosure of the group allocation until this step ensures that the operators standardize the insertion and opening phases of the Pap test. Cytopathologists who analyze the specimens are blinded to the study.

The modified and traditional Pap tests: All operators experienced in techniques for performing a Pap test should attend workshops for a standard operating procedure. The operators include family physicians and gynecologists. A well-trained research assistant is also responsible for ensuring standardization of procedures to eliminate interoperator variability. During the Pap test, there is a privacy curtain separating participants from the operators. An operator separates the labia with hand and then gently inserts the saline-lubricated speculum sideways. The speculum is rotated 90 degrees and opened to achieve an optimal view of the cervix. Then an operator fixes the speculum to obtain the cell samples by brushes. The above-standardized procedures are the same between the two groups. After preparing a specimen for conventional cytology, an operator loosens the locking nut of the speculum, partially closes the blade, rotates the speculum 90 degrees back to its original insertion orientation, and then removes the speculum in the control group receiving the traditional Pap test. For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds. Participants receiving the modified Pap test do not realize what is going on during the 15-second step because they are behind the privacy curtain. Procedurally, the subsequent addition of a non-painful step after specimen collection does not affect specimen quality.

Interview, Anthropometric Indices, and Anxiety scores: The investigators review the medical records after getting informed consent. In addition to pain evaluations, this project collects information about tobacco use, alcohol consumption, socioeconomic status, marital status, parity, sexually active status, menopause, predicted pain of Pap smears, psychological stress, anxiety score, analgesic use, current medications, and medical history through standardized personal interviews. Body height and weight are measured using a standard stadiometer, and body mass index is calculated. Blood pressure is measured with an electronic sphygmomanometer while the patient is seated after resting for at least five minutes. Psychological stress is assessed using the Brief Symptom Rating Scale -5 (BSRS-5). The BSRS-5 includes items of anxiety, depression, hostility, interpersonal sensitivity, and insomnia measured by a 5-point Likert-type scale of 0-4. Normal, slight, and great mental stress are defined by the sum of BSRS-5 scores ≤ 5, 6-9, and ≥10, respectively. The anxiety score is obtained using the Generalized Anxiety Disorder 7-item (GAD-7). GAD-7 total score for the seven items ranges from 0 to 21 (0-4: minimal anxiety. 5-9: mild anxiety. 10-14: moderate anxiety. 15-21: severe anxiety). Based on a meta-analysis, some experts have recommended considering using a cut-off of 8 to optimize sensitivity without compromising specificity.

Statistical analyses: For the descriptive analyses, values are presented as either numbers (percentages) or mean ± standard deviation. For the univariate analyses, categorical data are compared by the χ2 or Fisher's exact tests. Continuous data are compared using the independent T test. To compare screening uptake between trial groups, the investigators apply an ITT principle, such that outcomes are analyzed according to the trial groups assigned, regardless of whether the participants comply with the intervention components of each trial group. Logistic regression analyses are utilized to estimate the association of the intervention with the probability of 3-year and 1-year uptake of cervical cancer screening. The investigators use the five-region hypothesis test based on odds ratios to test the significant indistinguishability of real-time pain between the two groups for confirming the success of randomization and blinding. The effect sizes of five-minute recalled pain on a 1-5 numeric scale and a 0-10 VAS between the two groups are calculated using Glass's delta. Linear regression analyses are used to estimate the effect of the intervention on scores of 5-minute and 3-month recalled pains. Prespecified subgroup analyses using both linear and logistic regression analyses will be performed and summarized visually using forest plots. Major subgroups of interest include women who are never screened (never underwent Pap tests) and women who are under-screened (have not undergone Pap tests in the past 3 years). Statistical significance levels are determined by two-tailed tests (P \< 0.05). The statistical analyses are performed with SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA).

03

Conditions studied

  • Cervical Cancer Screening
  • Cervical Cancer Screening Methods

Keywords

  • Cancer screening participation
  • Cervical cancer
  • Multicenter
  • Multidisciplinary
  • Pain
  • Pap smear
  • Peak-end concept
  • Preventive medicine
  • Randomized controlled trial
04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 25 or above

Exclusion criteria

Exclusion Criteria:

  • Ongoing menstruation
  • Pregnancy
  • Incapability of understanding the numeric pain scales
  • Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or cancer)
  • Previous hysterectomy, pelvic surgery, or radiotherapy
  • Active vaginal or uterus infection
  • Analgesic use within 24 hours
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
850 participants (estimated)

Study arms

  • No intervention
    Traditional Pap test
  • Experimental
    Modified Pap test

    Procedure: Modified Pap test

Interventions

  • ProcedureModified Pap test

    For the intervention group receiving the modified Pap test, instead of immediately removing the speculum just after rotating back the speculum, an operator still fixes the speculum in the vagina for 15 seconds.

06

What researchers measure

Primary outcomes

  1. 3-year cervical cancer screening participation

    Defined as attending a Pap test at any clinic before the end of the 3rd subsequent year following study entry

    Time frame: 3 years

Secondary outcomes

  1. 1-year cervical cancer screening participation

    Defined as attending a Pap test at any clinic before the end of the next year following study entry

    Time frame: 1 year

  2. 5-minute recalled pain intensity on a 1-5 numeric scale and a 0-10 visual analog scale

    Recalled pain intensity at 5 minutes after the Pap smear test with evaluation by a 1-5 numeric scale and a 0-10 visual analog scale.

    Time frame: 5 minutes after receiving the Pap smear test

  3. 3-month recalled pain intensity on a 1-5 numeric scale and a 0-10 visual analog scale

    Recalled pain intensity at 3 months after the Pap smear test with evaluation by a 1-5 numeric scale and a 0-10 visual analog scale. To minimize potential propaganda for cervical cancer screening participation, the investigators choose the 3-month interval rather than 6-month or 1-year intervals for long-term pain recollection after Pap tests.

    Time frame: 3 months after receiving the Pap smear test

  4. Real time pain during the Pap test using a 1-5 numeric scale

    The participants will evaluate and record their pain every five seconds throughout the test with an application on a 1-to-5 numeric scale. The average pain, the maximal pain, and real-time pain at the beginning, first quarter, second quarter, third quarter, and the end of the regular course are compared between the two groups. The investigators will compare the average pain of each group's first and second half of the course. For participants receiving the modified Pap test, the investigators further compare the average pain, the maximal pain, and the last recorded real-time pain of the 15-second step with those of the regular course.

    Time frame: Every five seconds throughout the Pap test, up to completion of Pap test

Other outcomes

  1. Patient-reported feedback at the end of the study

    Patient-reported feedback at the health-service level drives revolutions and innovations. At the end of the study period (after the end of the third follow-up year in participants who do not undergo the 3-year cervical cancer screening after the study entry; or at least one month after the latest Pap test in participants who undergo the 3-year cervical cancer screening after the study entry), all participants will be asked to provide open-ended feedback for future qualitative research on Pap smear screening (detailed in subsequent research proposals). For instance, "Can you tell me more about your thoughts on Pap tests you have undergone these years?" or "What is your opinion on the future of Pap tests?".

    Time frame: At the fourth follow-up year in participants who do not undergo the 3-year cervical cancer screening; or between 1 and 12 months after the latest Pap test in participants who undergo the 3-year cervical cancer screening

07

Study locations

5 of 5 sites recruiting
  • National Taiwan University Hospital Yunlin Branch
    Douliu, Taiwan
    Recruiting
    • Tsung-Yi Yen, MD · Contactyantsungyi@gmail.com · 886 + 972656320
    • Chi-Huan Tsai, MD · Sub investigator
    • Tsung-Yi Yen, MD · Principal investigator
  • National Taiwan University Hospital Hsin-Chu Branch
    Hsinchu, Taiwan
    Recruiting
    • Ying-Cheng Chiang, MD, PhD · Contactycchiang@ntuh.gov.tw · 886 + 972653285
    • Ying-Cheng Chiang, MD, PhD · Principal investigator
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
    Recruiting
    • Chien-Hsieh Chiang, MD, MPH, PhD · Contactjiansie@gmail.com · 886 + 972651864
    • Chien-Hsieh Chiang, MD, MPH, PhD · Principal investigator
    • Shao-Yi Cheng, MD, MSc, DrPH · Sub investigator
    • Yi-Hsuan Lee, MD, MPH · Sub investigator
    • Ih-Jane Yang, MD · Sub investigator
    • Yi-Hua Lee, RN · Sub investigator
    • Chu-Chun Huang, MD, PhD · Sub investigator
  • National Taiwan University Cancer Center
    Taipei, Taiwan
    Recruiting
    • Ching-Ming Chiu, MD · Contactdreamerjimmy@msn.com · 886 + 972652923
    • Ching-Ming Chiu, MD · Principal investigator
  • National Taiwan University Hospital Beihu Branch
    Taipei, Taiwan
    Recruiting
08

References and documents

Publications

  • Jhuang JR, Lee WC, Chan CC. A randomized, double-blind water taste test to evaluate the equivalence of taste between tap water and filtered water in the Taipei metropolis. Sci Rep. 2020 Aug 7;10(1):13387. doi: 10.1038/s41598-020-70272-y. PubMed 32770131 ↗
  • Shih HY, Lee WC. A Five-Region Hypothesis Test for Exposure-Disease Associations. Sci Rep. 2017 Jul 11;7(1):5131. doi: 10.1038/s41598-017-05301-4. PubMed 28698548 ↗
  • Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31. doi: 10.1016/j.genhosppsych.2015.11.005. Epub 2015 Nov 18. PubMed 26719105 ↗
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Chen HC, Wu CH, Lee YJ, Liao SC, Lee MB. Validity of the five-item Brief Symptom Rating Scale among subjects admitted for general health screening. J Formos Med Assoc. 2005 Nov;104(11):824-9. PubMed 16496062 ↗
  • Chen CJ, Hong MK, Ding DC. Effective reduction in inadequate Pap smears by using a saline-lubricated speculum and two glass slides. Taiwan J Obstet Gynecol. 2020 Nov;59(6):906-909. doi: 10.1016/j.tjog.2020.09.018. PubMed 33218410 ↗
  • Sandkuhler J, Lee J. How to erase memory traces of pain and fear. Trends Neurosci. 2013 Jun;36(6):343-52. doi: 10.1016/j.tins.2013.03.004. Epub 2013 Apr 18. PubMed 23602194 ↗
  • Yen HK, Cheng SY, Chiu KN, Huang CC, Yu JY, Chiang CH; NTUH Pap Study Group. Adding a nonpainful end to reduce pain recollection of Pap smear screening: a randomized controlled trial. Pain. 2023 Aug 1;164(8):1709-1717. doi: 10.1097/j.pain.0000000000002897. Epub 2023 Apr 12. PubMed 37043729 ↗
  • Hsu CF, Propp L, Panetta L, Martin S, Dentakos S, Toplak ME, Eastwood JD. Mental effort and discomfort: Testing the peak-end effect during a cognitively demanding task. PLoS One. 2018 Feb 12;13(2):e0191479. doi: 10.1371/journal.pone.0191479. eCollection 2018. PubMed 29432429 ↗
  • Muller UWD, Witteman CLM, Spijker J, Alpers GW. All's Bad That Ends Bad: There Is a Peak-End Memory Bias in Anxiety. Front Psychol. 2019 Jun 12;10:1272. doi: 10.3389/fpsyg.2019.01272. eCollection 2019. PubMed 31249540 ↗
  • Schneider S, Stone AA, Schwartz JE, Broderick JE. Peak and end effects in patients' daily recall of pain and fatigue: a within-subjects analysis. J Pain. 2011 Feb;12(2):228-35. doi: 10.1016/j.jpain.2010.07.001. PubMed 20817615 ↗
  • Arney J, Hinojosa-Lindsey M, Street RL Jr, Hou J, El-Serag HB, Naik AD. Patient experiences with surveillance endoscopy: a qualitative study. Dig Dis Sci. 2014 Jul;59(7):1378-85. doi: 10.1007/s10620-014-3035-4. Epub 2014 Feb 6. PubMed 24500449 ↗
  • Redelmeier DA, Katz J, Kahneman D. Memories of colonoscopy: a randomized trial. Pain. 2003 Jul;104(1-2):187-94. doi: 10.1016/s0304-3959(03)00003-4. PubMed 12855328 ↗
  • Redelmeier DA, Kahneman D. Patients' memories of painful medical treatments: real-time and retrospective evaluations of two minimally invasive procedures. Pain. 1996 Jul;66(1):3-8. doi: 10.1016/0304-3959(96)02994-6. PubMed 8857625 ↗
  • Vlaeyen JWS, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: a state of the art. Pain. 2000 Apr;85(3):317-332. doi: 10.1016/S0304-3959(99)00242-0. PubMed 10781906 ↗
  • Lin SN, Taylor J, Alperstein S, Hoda R, Holcomb K. Does speculum lubricant affect liquid-based Papanicolaou test adequacy? Cancer Cytopathol. 2014 Mar;122(3):221-6. doi: 10.1002/cncy.21369. Epub 2013 Nov 19. PubMed 24254917 ↗
  • Uygur D, Guler T, Yayci E, Atacag T, Comunoglu C, Kuzey GM. Association of speculum lubrication with pain and Papanicolaou test accuracy. J Am Board Fam Med. 2012 Nov-Dec;25(6):798-804. doi: 10.3122/jabfm.2012.06.120021. PubMed 23136318 ↗
  • Keskin AE, Onaran Y, Duvan IC, Simavli S, Kafali H. Topical anesthetic (lidocaine-prilocaine) cream application before speculum examination in postmenopausal women. J Minim Invasive Gynecol. 2012 May-Jun;19(3):350-5. doi: 10.1016/j.jmig.2012.01.005. Epub 2012 Mar 13. PubMed 22417905 ↗
  • Simavli S, Kaygusuz I, Kinay T, Cukur S. The role of gel application in decreasing pain during speculum examination and its effects on papanicolaou smear results. Arch Gynecol Obstet. 2014 Apr;289(4):809-15. doi: 10.1007/s00404-013-3047-x. Epub 2013 Oct 12. PubMed 24121692 ↗
  • Leung SS, Leung I. Cervical cancer screening: knowledge, health perception and attendance rate among Hong Kong Chinese women. Int J Womens Health. 2010 Aug 9;2:221-8. doi: 10.2147/ijwh.s10724. PubMed 21072314 ↗
  • Song W, Li H, Sun F, Guo T, Jiang S, Wang X. Pain Avoidance and Its Relation to Neural Response to Punishment Characterizes Suicide Attempters with Major Depression Disorder. Psychiatry Res. 2020 Dec;294:113507. doi: 10.1016/j.psychres.2020.113507. Epub 2020 Oct 13. PubMed 33075650 ↗
  • Claes N, Crombez G, Vlaeyen JWS. Pain-avoidance versus reward-seeking: an experimental investigation. Pain. 2015 Aug;156(8):1449-1457. doi: 10.1097/j.pain.0000000000000116. PubMed 25775360 ↗
  • Gauss JW, Mabiso A, Williams KP. Pap screening goals and perceptions of pain among black, Latina, and Arab women: steps toward breaking down psychological barriers. J Cancer Educ. 2013 Jun;28(2):367-74. doi: 10.1007/s13187-012-0441-1. PubMed 23288606 ↗
  • Hoyo C, Yarnall KS, Skinner CS, Moorman PG, Sellers D, Reid L. Pain predicts non-adherence to pap smear screening among middle-aged African American women. Prev Med. 2005 Aug;41(2):439-45. doi: 10.1016/j.ypmed.2004.11.021. PubMed 15917039 ↗
  • Masson H. Cervical pap smears and pandemics: The effect of COVID-19 on screening uptake & opportunities to improve. Womens Health (Lond). 2021 Jan-Dec;17:17455065211017070. doi: 10.1177/17455065211017070. PubMed 34032158 ↗
  • Holroyd E, Twinn S, Adab P. Socio-cultural influences on Chinese women's attendance for cervical screening. J Adv Nurs. 2004 Apr;46(1):42-52. doi: 10.1111/j.1365-2648.2003.02964.x. PubMed 15030441 ↗
  • Kaneko N. Factors associated with cervical cancer screening among young unmarried Japanese women: results from an internet-based survey. BMC Womens Health. 2018 Jul 31;18(1):132. doi: 10.1186/s12905-018-0623-z. PubMed 30064505 ↗
  • Friedman AM, Hemler JR, Rossetti E, Clemow LP, Ferrante JM. Obese women's barriers to mammography and pap smear: the possible role of personality. Obesity (Silver Spring). 2012 Aug;20(8):1611-7. doi: 10.1038/oby.2012.50. Epub 2012 Feb 28. PubMed 22370590 ↗
  • Chou HH, Huang HJ, Cheng HH, Chang CJ, Yang LY, Huang CC, Chang WY, Hsueh S, Chao A, Wang CJ, Tang YH, Lin CT, Qiu JT, Chen MY, Chen CY, Huang KG, Tsai TC, Chang TC, Lai CH. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J Formos Med Assoc. 2016 Dec;115(12):1089-1096. doi: 10.1016/j.jfma.2015.10.014. Epub 2015 Dec 23. PubMed 26723863 ↗
  • Yang CM, Sung FC, Hsue CS, Muo CH, Wang SW, Shieh SH. Comparisons of Papanicolaou Utilization and Cervical Cancer Detection between Rural and Urban Women in Taiwan. Int J Environ Res Public Health. 2020 Dec 28;18(1):149. doi: 10.3390/ijerph18010149. PubMed 33379209 ↗
  • Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med. 2004 Mar;19(3):243-50. doi: 10.1111/j.1525-1497.2004.21107.x. PubMed 15009779 ↗
  • Dugue PA, Lynge E, Rebolj M. Mortality of non-participants in cervical screening: Register-based cohort study. Int J Cancer. 2014 Jun 1;134(11):2674-82. doi: 10.1002/ijc.28586. Epub 2013 Nov 29. PubMed 24288241 ↗
  • Andrae B, Andersson TM, Lambert PC, Kemetli L, Silfverdal L, Strander B, Ryd W, Dillner J, Tornberg S, Sparen P. Screening and cervical cancer cure: population based cohort study. BMJ. 2012 Mar 1;344:e900. doi: 10.1136/bmj.e900. PubMed 22381677 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2030, 57 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 57 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2025
First posted
May 13, 2025
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2032
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
248→850
Oct 30, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionReal time pain during the Pap test using a 1-5 numeric scale: how it is measured was reworded
Oct 28, 2026
Contact
Study contact changed: j•••@gmail.com→j•••@gmail.com · •••9146. See the current contact
Oct 28, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • National Taiwan University Hospital Yunlin Branch · Douliu, TaiwanContact 0•••@ntuh.gov.tw · •••3456→y•••@gmail.com · •••6320Contact person changed (no phone or email listed)
  • National Taiwan University Hospital · Taipei, TaiwanContact added (no phone or email listed)
Oct 28, 2026
Show all 2 updates
  1. Oct 30, 2026
    Enrollment 248→850
  2. Oct 28, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionReal time pain during the Pap test using a 1-5 numeric scale: how it is measured was reworded
    Contact Study contact changed: j•••@gmail.com→j•••@gmail.com · •••9146. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • National Taiwan University Hospital Yunlin Branch · Douliu, TaiwanContact 0•••@ntuh.gov.tw · •••3456→y•••@gmail.com · •••6320Contact person changed (no phone or email listed)
    • National Taiwan University Hospital · Taipei, TaiwanContact added (no phone or email listed)
    + 3 other changes: verification date, date precision and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06968871
Collaborators
National Taiwan University Hospital Hsin-Chu Branch, National Taiwan University, National Taiwan University Hospital Beihu Branch, National Taiwan University Hospital, Yun-Lin Branch, National Science and Technology Council
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Mar 1, 2026
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 30, 2026

Study contacts

Chien-Hsieh Chiang, MD, MPH, PhD
Contact
jiansie@gmail.com
886 + 972651864
Yong-Jie Ting, MD
Contact
jessie50626@gmail.com
886 + 981619146
Chien-Hsieh Chiang, MD, MPH, PhD
study chair · National Taiwan University Hospital & College of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion